Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoarthritis | 24 | 2024 | 287 | 7.310 |
Why?
|
| Arthralgia | 10 | 2023 | 100 | 4.030 |
Why?
|
| Osteoarthritis, Knee | 9 | 2023 | 299 | 3.380 |
Why?
|
| Pain | 15 | 2024 | 332 | 3.230 |
Why?
|
| Nociceptors | 6 | 2023 | 19 | 2.590 |
Why?
|
| Hyperalgesia | 8 | 2024 | 46 | 2.280 |
Why?
|
| Animals | 38 | 2024 | 3271 | 2.280 |
Why?
|
| Ganglia, Spinal | 12 | 2024 | 58 | 2.260 |
Why?
|
| Mice | 26 | 2024 | 1240 | 2.000 |
Why?
|
| Arthritis, Experimental | 6 | 2020 | 52 | 1.910 |
Why?
|
| Disease Models, Animal | 20 | 2024 | 526 | 1.810 |
Why?
|
| Knee Joint | 5 | 2024 | 572 | 1.360 |
Why?
|
| Receptors, CCR2 | 4 | 2021 | 10 | 1.320 |
Why?
|
| Neurons | 3 | 2017 | 273 | 1.300 |
Why?
|
| Immunity, Innate | 3 | 2020 | 46 | 1.260 |
Why?
|
| Nerve Growth Factor | 3 | 2024 | 41 | 1.240 |
Why?
|
| Mice, Inbred C57BL | 13 | 2024 | 363 | 1.230 |
Why?
|
| Cartilage, Articular | 6 | 2018 | 268 | 1.140 |
Why?
|
| Mice, Transgenic | 3 | 2024 | 175 | 1.010 |
Why?
|
| Chemokine CCL2 | 5 | 2018 | 19 | 0.940 |
Why?
|
| Macrophages | 2 | 2024 | 79 | 0.930 |
Why?
|
| Neuroimmunomodulation | 3 | 2020 | 8 | 0.930 |
Why?
|
| Insulin-Like Growth Factor I | 5 | 2014 | 56 | 0.910 |
Why?
|
| Microscopy | 1 | 2024 | 10 | 0.870 |
Why?
|
| Chronic Pain | 5 | 2022 | 127 | 0.860 |
Why?
|
| Peptides | 3 | 2014 | 89 | 0.860 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2024 | 152 | 0.820 |
Why?
|
| Synovitis | 2 | 2022 | 20 | 0.800 |
Why?
|
| Nociception | 4 | 2019 | 10 | 0.760 |
Why?
|
| Male | 18 | 2024 | 12659 | 0.750 |
Why?
|
| Behavior, Animal | 2 | 2024 | 47 | 0.740 |
Why?
|
| Tissue Engineering | 2 | 2011 | 24 | 0.680 |
Why?
|
| Calcium | 3 | 2018 | 370 | 0.640 |
Why?
|
| Gene Expression | 2 | 2020 | 180 | 0.620 |
Why?
|
| Toll-Like Receptors | 1 | 2019 | 14 | 0.610 |
Why?
|
| Pain Management | 2 | 2018 | 126 | 0.610 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 55 | 0.600 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 164 | 0.600 |
Why?
|
| Humans | 26 | 2023 | 23187 | 0.600 |
Why?
|
| Aggrecans | 2 | 2018 | 52 | 0.570 |
Why?
|
| Cytokines | 3 | 2019 | 192 | 0.570 |
Why?
|
| Mice, Knockout | 6 | 2023 | 276 | 0.570 |
Why?
|
| ADAM Proteins | 2 | 2015 | 41 | 0.570 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2018 | 25 | 0.550 |
Why?
|
| Cannabinoids | 1 | 2017 | 4 | 0.530 |
Why?
|
| Phytotherapy | 1 | 2017 | 11 | 0.530 |
Why?
|
| Cannabis | 1 | 2017 | 10 | 0.530 |
Why?
|
| Clozapine | 1 | 2017 | 5 | 0.520 |
Why?
|
| Neural Inhibition | 1 | 2017 | 8 | 0.520 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2023 | 22 | 0.510 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2017 | 17 | 0.500 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 272 | 0.500 |
Why?
|
| Stifle | 1 | 2015 | 9 | 0.460 |
Why?
|
| Antibodies, Neutralizing | 1 | 2015 | 17 | 0.460 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2011 | 16 | 0.440 |
Why?
|
| Menisci, Tibial | 4 | 2020 | 95 | 0.430 |
Why?
|
| Tissue Scaffolds | 2 | 2011 | 21 | 0.430 |
Why?
|
| Joints | 1 | 2014 | 67 | 0.410 |
Why?
|
| Protease Inhibitors | 1 | 2013 | 7 | 0.400 |
Why?
|
| Peptide Hydrolases | 1 | 2013 | 8 | 0.400 |
Why?
|
| Orthopedic Procedures | 1 | 2014 | 225 | 0.360 |
Why?
|
| Female | 8 | 2024 | 13142 | 0.360 |
Why?
|
| Drug Carriers | 1 | 2011 | 5 | 0.360 |
Why?
|
| Blood Coagulation | 3 | 2006 | 20 | 0.350 |
Why?
|
| Heparin | 2 | 2010 | 22 | 0.350 |
Why?
|
| Nerve Growth Factors | 2 | 2023 | 33 | 0.350 |
Why?
|
| Ehlers-Danlos Syndrome | 2 | 2021 | 9 | 0.340 |
Why?
|
| Chondroitin Sulfates | 1 | 2010 | 5 | 0.330 |
Why?
|
| Chondrogenesis | 1 | 2010 | 24 | 0.330 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2010 | 27 | 0.320 |
Why?
|
| Plasma | 2 | 2006 | 13 | 0.300 |
Why?
|
| Cells, Cultured | 4 | 2015 | 462 | 0.290 |
Why?
|
| RNA, Messenger | 3 | 2023 | 283 | 0.280 |
Why?
|
| Disease Progression | 2 | 2020 | 547 | 0.270 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2017 | 53 | 0.260 |
Why?
|
| Synovial Membrane | 3 | 2022 | 48 | 0.260 |
Why?
|
| ADAMTS5 Protein | 2 | 2018 | 20 | 0.260 |
Why?
|
| Signal Transduction | 3 | 2023 | 387 | 0.250 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2006 | 39 | 0.230 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 338 | 0.220 |
Why?
|
| Models, Theoretical | 3 | 2020 | 76 | 0.220 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 192 | 0.220 |
Why?
|
| Immunophenotyping | 1 | 2023 | 28 | 0.200 |
Why?
|
| Hydrogels | 3 | 2014 | 7 | 0.200 |
Why?
|
| Cattle | 3 | 2014 | 109 | 0.200 |
Why?
|
| Chondrocytes | 2 | 2014 | 99 | 0.190 |
Why?
|
| Analgesics | 2 | 2020 | 78 | 0.180 |
Why?
|
| Diabetic Neuropathies | 1 | 2022 | 11 | 0.180 |
Why?
|
| Skin Abnormalities | 1 | 2021 | 2 | 0.180 |
Why?
|
| Connective Tissue Diseases | 1 | 2021 | 7 | 0.180 |
Why?
|
| Infant | 1 | 2023 | 483 | 0.180 |
Why?
|
| Ion Channels | 1 | 2023 | 204 | 0.170 |
Why?
|
| Sensory Receptor Cells | 1 | 2021 | 9 | 0.170 |
Why?
|
| Radiography | 2 | 2014 | 521 | 0.170 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 107 | 0.170 |
Why?
|
| Bone Marrow Cells | 2 | 2011 | 49 | 0.170 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 98 | 0.160 |
Why?
|
| Musculoskeletal Pain | 1 | 2020 | 19 | 0.160 |
Why?
|
| Microarray Analysis | 1 | 2020 | 6 | 0.160 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2019 | 2 | 0.160 |
Why?
|
| Spinal Cord Dorsal Horn | 1 | 2019 | 7 | 0.160 |
Why?
|
| Alarmins | 1 | 2019 | 2 | 0.160 |
Why?
|
| Biomarkers | 2 | 2019 | 486 | 0.150 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 109 | 0.150 |
Why?
|
| Phenotype | 1 | 2020 | 260 | 0.150 |
Why?
|
| Rats | 2 | 2018 | 622 | 0.140 |
Why?
|
| ADAMTS4 Protein | 1 | 2018 | 15 | 0.140 |
Why?
|
| Matrix Metalloproteinases | 1 | 2018 | 18 | 0.140 |
Why?
|
| Ganglion Cysts | 1 | 2018 | 6 | 0.140 |
Why?
|
| Joint Instability | 1 | 2021 | 312 | 0.140 |
Why?
|
| Random Allocation | 2 | 2016 | 102 | 0.140 |
Why?
|
| Central Nervous System Sensitization | 1 | 2017 | 3 | 0.140 |
Why?
|
| TRPC Cation Channels | 1 | 2017 | 4 | 0.140 |
Why?
|
| Albuminuria | 1 | 2017 | 7 | 0.140 |
Why?
|
| Dronabinol | 1 | 2017 | 1 | 0.130 |
Why?
|
| Cannabidiol | 1 | 2017 | 3 | 0.130 |
Why?
|
| Receptors, CCR7 | 1 | 2017 | 7 | 0.130 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 314 | 0.130 |
Why?
|
| NAV1.8 Voltage-Gated Sodium Channel | 1 | 2017 | 6 | 0.130 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 22 | 0.130 |
Why?
|
| Catalysis | 3 | 2013 | 15 | 0.130 |
Why?
|
| Chemokines, CC | 1 | 2017 | 3 | 0.130 |
Why?
|
| Patch-Clamp Techniques | 1 | 2017 | 97 | 0.130 |
Why?
|
| Kidney Diseases | 1 | 2017 | 69 | 0.130 |
Why?
|
| Osteonecrosis | 1 | 2017 | 13 | 0.130 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 2 | 2014 | 2 | 0.130 |
Why?
|
| Drug Design | 2 | 2014 | 20 | 0.130 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 22 | 0.130 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 565 | 0.130 |
Why?
|
| Spinal Cord | 1 | 2017 | 74 | 0.130 |
Why?
|
| Chemokine CX3CL1 | 1 | 2016 | 2 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 83 | 0.120 |
Why?
|
| Pain Measurement | 1 | 2018 | 412 | 0.120 |
Why?
|
| Calgranulin A | 1 | 2015 | 5 | 0.120 |
Why?
|
| alpha-Macroglobulins | 1 | 2015 | 12 | 0.120 |
Why?
|
| Microglia | 1 | 2016 | 108 | 0.120 |
Why?
|
| Adsorption | 2 | 2014 | 4 | 0.120 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 8 | 0.120 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 14 | 0.120 |
Why?
|
| Tibial Meniscus Injuries | 1 | 2015 | 46 | 0.110 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2014 | 2 | 0.110 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 28 | 0.110 |
Why?
|
| Horses | 1 | 2014 | 7 | 0.110 |
Why?
|
| Dogs | 1 | 2014 | 136 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2015 | 171 | 0.110 |
Why?
|
| Animals, Genetically Modified | 1 | 2013 | 17 | 0.100 |
Why?
|
| Structure-Activity Relationship | 1 | 2013 | 30 | 0.100 |
Why?
|
| Biomechanical Phenomena | 1 | 2014 | 537 | 0.090 |
Why?
|
| Biotinylation | 1 | 2011 | 1 | 0.090 |
Why?
|
| Streptavidin | 1 | 2011 | 3 | 0.090 |
Why?
|
| Fluorometry | 1 | 2011 | 5 | 0.090 |
Why?
|
| Tissue Culture Techniques | 1 | 2011 | 7 | 0.090 |
Why?
|
| Glycosaminoglycans | 1 | 2011 | 18 | 0.090 |
Why?
|
| Solubility | 1 | 2011 | 18 | 0.090 |
Why?
|
| Protein Conformation | 1 | 2011 | 63 | 0.090 |
Why?
|
| Stromal Cells | 1 | 2011 | 33 | 0.090 |
Why?
|
| DNA | 1 | 2011 | 94 | 0.090 |
Why?
|
| Kinetics | 1 | 2011 | 174 | 0.090 |
Why?
|
| Proteoglycans | 1 | 2011 | 120 | 0.090 |
Why?
|
| Heparitin Sulfate | 1 | 2010 | 3 | 0.080 |
Why?
|
| Polysaccharide-Lyases | 1 | 2010 | 4 | 0.080 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 2010 | 3 | 0.080 |
Why?
|
| Regeneration | 1 | 2010 | 15 | 0.080 |
Why?
|
| Models, Animal | 1 | 2010 | 103 | 0.080 |
Why?
|
| Injections, Intra-Articular | 1 | 2010 | 56 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 875 | 0.080 |
Why?
|
| Lipopolysaccharides | 2 | 2023 | 85 | 0.080 |
Why?
|
| Dexamethasone | 1 | 2010 | 34 | 0.080 |
Why?
|
| Rabbits | 1 | 2010 | 165 | 0.080 |
Why?
|
| Arthroscopy | 1 | 2014 | 552 | 0.080 |
Why?
|
| Surface Properties | 2 | 2006 | 103 | 0.070 |
Why?
|
| Protein Engineering | 1 | 2008 | 6 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 45 | 0.070 |
Why?
|
| Models, Biological | 2 | 2005 | 302 | 0.060 |
Why?
|
| Mutation | 2 | 2020 | 330 | 0.060 |
Why?
|
| Silanes | 1 | 2006 | 1 | 0.060 |
Why?
|
| Microscopy, Atomic Force | 1 | 2006 | 4 | 0.060 |
Why?
|
| Factor XII | 1 | 2005 | 1 | 0.060 |
Why?
|
| Prothrombin | 1 | 2005 | 4 | 0.060 |
Why?
|
| Coagulants | 1 | 2005 | 11 | 0.060 |
Why?
|
| Biocompatible Materials | 1 | 2005 | 68 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2023 | 40 | 0.050 |
Why?
|
| Mitochondria | 1 | 2022 | 55 | 0.040 |
Why?
|
| Calcium Channels | 1 | 2022 | 106 | 0.040 |
Why?
|
| Collagen Type V | 1 | 2020 | 3 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 445 | 0.040 |
Why?
|
| Inflammation | 1 | 2022 | 230 | 0.040 |
Why?
|
| Skin | 1 | 2020 | 117 | 0.040 |
Why?
|
| Neurons, Afferent | 1 | 2018 | 6 | 0.030 |
Why?
|
| Aged | 2 | 2022 | 7660 | 0.030 |
Why?
|
| Sesquiterpenes, Guaiane | 1 | 2017 | 1 | 0.030 |
Why?
|
| Piperidines | 1 | 2017 | 13 | 0.030 |
Why?
|
| Indoles | 1 | 2017 | 32 | 0.030 |
Why?
|
| Podocytes | 1 | 2017 | 36 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2016 | 32 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 131 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 169 | 0.030 |
Why?
|
| Cricetinae | 1 | 2015 | 33 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2015 | 59 | 0.030 |
Why?
|
| Epitopes | 1 | 2015 | 39 | 0.030 |
Why?
|
| Crystallization | 1 | 2014 | 3 | 0.030 |
Why?
|
| Diffusion | 1 | 2014 | 24 | 0.030 |
Why?
|
| Cell Survival | 1 | 2014 | 99 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 161 | 0.030 |
Why?
|
| Materials Testing | 1 | 2014 | 101 | 0.030 |
Why?
|
| Hypertension | 1 | 2015 | 169 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2014 | 164 | 0.030 |
Why?
|
| Brain | 1 | 2017 | 1241 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2008 | 9 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 28 | 0.020 |
Why?
|
| Binding Sites | 1 | 2008 | 67 | 0.020 |
Why?
|
| Protein Binding | 1 | 2008 | 112 | 0.020 |
Why?
|
| Adult | 1 | 2017 | 6959 | 0.020 |
Why?
|
| Factor XIIa | 1 | 2005 | 1 | 0.010 |
Why?
|
| Titrimetry | 1 | 2005 | 3 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2005 | 35 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 2005 | 11 | 0.010 |
Why?
|
| Thrombin | 1 | 2005 | 14 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 7981 | 0.010 |
Why?
|
| Blood Coagulation Factors | 1 | 2005 | 19 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 116 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 1264 | 0.010 |
Why?
|